Q3 FY2026 · ended Sep 30, 2026 · Revenue $3.99M, +78.3% YoY · Filed Oct 30, 2026
Omniab, Inc. (OABI) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $4.0 million and a net loss of $15.7 million. Free cash flow was $10.6 million. As of Sep 30, 2026 it held $64.2 million in cash and investments and $18.1 million in total debt.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- OABI (Nasdaq), OABIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1846253
- Former names
- Avista Public Acquisition Corp. II (until Nov 1, 2022)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $4.0M | $13.4M | $14.4M | $8.4M | $2.2M |
| Operating income | -$16.4M | -$6.6M | -$7.8M | -$15.8M | -$18.1M |
| Net income | -$15.7M | -$5.9M | -$7.7M | -$14.2M | -$16.5M |
| Diluted EPS | -$0.12 | -$0.05 | -$0.06 | -$0.11 | -$0.14 |
| Operating cash flow | $10.6M | $2.7M | -$4.9M | -$5.7M | -$9.8M |
| Free cash flow | $10.6M | $2.6M | -$5.1M | -$5.7M | -$9.9M |
| Total assets | $290.9M | $290.3M | $293.6M | $300.9M | $309.7M |
| Total liabilities | $41.8M | $30.0M | $31.0M | $33.9M | $32.2M |
| Stockholders' equity | $249.2M | $260.3M | $262.6M | $267.0M | $277.4M |
| Cash and investments | $64.2M | $52.0M | $49.1M | $54.0M | $59.5M |
| Total debt | $18.1M | $18.9M | $19.7M | $20.3M | $21.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 30, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
All 387 Omniab, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.